Commission welcomes signs of stability for devices unit
This article was originally published in Clinica
As can be seen from a glance at Clinica this week, the medical device experts at the European Commission have returned from their summer break to a mountain of issues - but whatever the workload, there is a general relief that the intention is for the unit responsible for medical devices to keep its autonomy in the new Commission within Directorate General Enterprise and Industry.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.